



Notification of release of escrowed shares

Sydney, Australia, Friday, 10 May 2019: Australian medical technology company, Next Science Limited ACN 622 382 549 (ASX:NXS) (**Next Science**), advises, in accordance with Listing Rule 3.10A, that 2,270,294 fully paid ordinary shares in Next Science (**Escrowed Shares**) will be released from escrow on 25 May 2019.

The Escrowed Shares have been subject to an ASX imposed escrow restriction for a period of 12 months from the date of issue of the shares.

- - - END - - -

For further information, please contact:

Investor inquiries

Judith Mitchell, Managing Director
Phone: +61 2 8607 5124
Email: jmitchell@nextscience.com

Partnering inquiries

Byron Darroch, Executive VP, Partnerships
Phone: +61 2 8607 5124
Email: bdarroch@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology.

For further information visit: www.nextscience.com.